Company:  DENALI THERAPEUTICS INC. (DNLI)
Form Type:  10-Q
Filing Date:  8/6/2019 
CIK:  0001714899 
Address:  161 OYSTER POINT BLVD. 
City, State, Zip:  SOUTH SAN FRANCISCO, California 94080 
Telephone:  (650) 866-8548 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$15.38  
Change: 
0.18 (1.18%)  
Trade Time: 
Oct 11  
Market Cap: 
$1.47B
Trade DNLI now with 

© 2019  
Description of Business
Neurodegeneration represents one of the most significant unmet medical needs of our time, with few effective therapeutic options available for patients with Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis ("ALS"), and other neurodegenerative diseases. The burden of these diseases to patients and society is massive. We believe the time is right to make a strong and ambitious effort to defeat neurodegeneration. We believe that we can succeed in a field that has seen limited success in the past, because of our team of experienced and passionately dedicated scientists and drug developers, our focused scientific strategy, and our proprietary blood-brain barrier ("BBB"), platform delivery technology. We are developing a broad portfolio of targeted therapeutic candidates for neurodegenerative diseases and currently have two programs in Phase 1 clinical development.
Register and access this filing in:     
  FORM 10-Q
    PART I. FINANCIAL INFORMATION
      ITEM 1. FINANCIAL STATEMENTS
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        Notes to Condensed Consolidated Financial Statements
      ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL ...
      ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT ...
      ITEM 4. CONTROLS AND PROCEDURES
    PART II. OTHER INFORMATION
      ITEM 1. LEGAL PROCEEDINGS
      ITEM 1A. RISK FACTORS
      ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF ...
      ITEM 3. DEFAULTS UPON SENIOR SECURITIES
      ITEM 4. MINE SAFETY DISCLOSURES
      ITEM 5. OTHER INFORMATION
      ITEM 6. EXHIBITS
    EXHIBIT INDEX
    SIGNATURES
  EXHIBIT 31.1
    CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
  EXHIBIT 31.2
    CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
  EXHIBIT 32.1
    CERTIFICATION OF CHIEF EXECUTIVE OFFICER
  EXHIBIT 32.2
    CERTIFICATION OF CHIEF FINANCIAL OFFICER